Fonte: Lancet oncology. Unidade: FM
Assuntos: NEOPLASIAS PROSTÁTICAS, METÁSTASE NEOPLÁSICA, NEOPLASIAS ÓSSEAS, ESTEROIDES, ANDRÓGENOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SMITH, Matthew et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, v. 20, n. 3, p. 408-419, 2019Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(18)30860-X. Acesso em: 30 ago. 2024.APA
Smith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., et al. (2019). Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, 20( 3), 408-419. doi:10.1016/S1470-2045(18)30860-XNLM
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Nahas WC. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet oncology. 2019 ; 20( 3): 408-419.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S1470-2045(18)30860-XVancouver
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Nahas WC. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet oncology. 2019 ; 20( 3): 408-419.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S1470-2045(18)30860-X
